AbCellera Biologics (ABCL) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 176.1% versus a loss of 1.3%. Over five years, VRDN leads with a +63.7% price change compared with -30.7% for ABCL. Viridian Therapeutics is the larger company by market cap ($3.40 billion vs $3.16 billion), about 1.1 times the size.
AbCellera Biologics converts more of its revenue into profit, with a net margin of -194.9% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | VRDN |
|---|---|---|
| Share price | $9.69 | $29.96 |
| Market cap | $3.16B | $3.40B |
| 1-day change | -7.45% | -4.71% |
| YTD return | +183.33% | -3.73% |
| 1-year return | +176.07% | -1.25% |
| 5-year return | -30.74% | +63.72% |
| EPS (TTM) | $-0.48 | $-3.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $70.85M |
| Revenue growth (YoY) | +160.56% | +23359.93% |
| Net income (latest FY) | $-146.41M | $-342.60M |
| Operating margin | -288.98% | -512.91% |
| Net margin | -194.88% | -483.57% |
| 52-week high | $15.02 | $34.29 |
| 52-week low | $2.75 | $13.18 |
| Distance from 52-week high | -35.46% | -12.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +92.67% | +42.72% |
| Average volume | 4.34M | 2.14M |
| Shares outstanding | 326.62M | 113.56M |
| Employees | 562 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed VRDN by 177.3 percentage points over the past year.
- AbCellera Biologics is more profitable, keeping -194.9 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +160.56%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
ABCL vs VRDN FAQ
Which is bigger, AbCellera Biologics or Viridian Therapeutics?
Viridian Therapeutics (VRDN) is larger, with a market capitalization of $3.40B compared with $3.16B for AbCellera Biologics (ABCL).
Which stock has performed better over the past year, ABCL or VRDN?
ABCL returned +176.07% over the past 12 months, compared with -1.25% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.